First-line pembrolizumab plus androgen deprivation therapy for locally advanced microsatellite instability-high prostate cancer in a patient with Muir-Torre syndrome: A case report
Mohammad Atiq(Memorial Sloan Kettering Cancer Center), Ravi A. Madan(National Cancer Institute), Isaac Brownell(National Institute of Arthritis and Musculoskeletal and Skin Diseases), Lisa M. Cordes(National Institutes of Health Clinical Center), Amy Hankin(National Institutes of Health), Barış Türkbey(National Institutes of Health), Fatima Karzai(National Institutes of Health), Gregory T. Chesnut(Uniformed Services University of the Health Sciences), Yi Liu(WinnMed), Danielle M. Pastor(National Institutes of Health)
Cited by 1
Related Papers
Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors
|Clinical Cancer Research|2018|415
The Abscopal Effect Associated With a Systemic Anti-melanoma Immune Response
|International Journal of Radiation Oncology*Biology*Physics|2013|380
Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial
|The Lancet Oncology|2012|327
Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations
|Journal for ImmunoTherapy of Cancer|2018|314
Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer
|Cancer Immunology Immunotherapy|2009|298